Co‐administration of intravesical bacillus Calmette‐Guérin and interferon α‐2B as first line in treating superficial transitional cell carcinoma of the urinary bladdera

• DOI: 10.1111/j.1464-410x.2010.10040.x
• Publication Date: 2011-02-18T17:13:21Z
• Authors: Shouki Bazarbashi; Hussein Soudy; Mahmoud Abdelsalam; Ali Al‐Jubran; Saad Akhtar; Muhammad Memon; Muhammad Aslam; Said Kattan; Mohamed Shoukri
• Keywords: Dysuria; Carcinoma in situ

Study Type – Therapy (individual cohort) Level of Evidence 2b What’s known on the subject? and What does study add? BCG is standard treatment for superficial bladder cancer. The combination interferon‐alfa may be more effective less toxic than alone. With long term follow up efficacy toxicity combined intravesical interferon‐α alone seems to equal in OBJECTIVE • To evaluate bacillus Calmette‐Guérin (BCG) interferon α‐2B (IFNα‐2B) treating cancer (SBC). mentioned has shown synergism pre‐clinical studies. PATIENTS AND METHODS present a single‐arm, open‐label, single‐institution prospective trial. Patients with Ta, T1 or situ carcinoma no previous therapy were included between July 2002 June 2009. treated weekly instillation 27 mg mixed 10 million units (MU) IFNα‐2B six consecutive weeks followed by 3‐weekly booster instillations at 3 months if there was recurrence. primary endpoint disease Secondary endpoints progression toxicity. followed‐up cystoscopy urine cytology every months. RESULTS In all, 50 patients included. At median follow‐up 55.8 months, 31 (62%) recurrence‐free. Progression muscle invasion occurred two (4%) metastasis patients. Treatment well tolerated, grade III dysuria frequency occurring 18 14% patients, respectively, 74% being able complete maintenance dosage. CONCLUSION patient population SBC similar monotherapy.